JAK2

(redirected from Janus kinase 2)
Also found in: Wikipedia.

JAK2

A gene on chromosome 9p24 that encodes a non-receptor protein tyrosine kinase, which is involved in a subset of cytokine receptor signalling pathways, including for cell growth, development, differentiation and histone modifications. JAK2 mediates essential signalling events in both innate and adaptive immunity, and is required for responses to gamma interferon. It plays a key role in signal transduction by associating with type-I receptors (e.g., growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin (THPO)) or type-II receptors (e.g., IFN-alpha, IFN-beta, IFN-gamma and a wide range of interleukins).
References in periodicals archive ?
The CALR diagnostic that is under development is expected to be highly complementary to QIAGEN's currently marketed kits for a key mutation of the Janus kinase 2 (JAK2) gene.
The JAK2V617F mutation induces a loss of inhibitory activity of the JH2 pseudokinase part on the JH1 kinase part of Janus kinase 2 (JAK2).
The JAK2V617F mutation induces a loss of inhibitory activity of the JH2 pseuclokinase part on the JH1 kinase part of Janus kinase 2 (JAK2).
TareGen's TG101348 aims to block the effects of an enzyme known as Janus kinase 2, Sanofi said.
The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor.
a leading national provider of physician-based anatomic pathology, has developed a new assay that detects and quantifies a mutation in the Janus kinase 2 (JAK2) gene common in bcr/abl-negative myeloproliferative disorders (MPDs).
24-week results of a blinded phase 2b dose-ranging study of baricitinib, an oral janus kinase 1/ janus kinase 2 inhibitor, in combination with traditional disease modifying antirheumatic drugs in patients with rheumatoid arthritis.
12- and 24-Week Patient-Reported Outcomes from a Phase IIb Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1 / Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
titled "Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes," is available at http://jco.
20, 2010 /PRNewswire/ -- Ambit Biosciences (Ambit), today announced that it has initiated separate Phase I trials for two products AC430, a selective Janus Kinase 2 (JAK2) inhibitor, and AC480, a pan-HER inhibitor.
today announced that it has acquired an option to license rights to SB1518, an orally available, potent, and selective inhibitor of Janus Kinase 2 (JAK2), and SB1578, also a JAK2 inhibitor, from S*BIO Pte Ltd based in Singapore.